Accent Therapeutics - Crunchbase Company Profile & Funding

Q: Who invested in Accent Therapeutics?

Accent Therapeutics has 13 investors including Bristol-Myers Squibb And Atlas Venture.

Q: How much funding has Accent Therapeutics raised to date?

Accent Therapeutics has raised obfuscated.

Overview

Accent Therapeutics

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

+2 more milestones

See more interactive data and historical milestones on desktop for the best experience

About Accent Therapeutics

CB Rank

12222

Accent Therapeutics is a biopharmaceutical company.

Founded

obfuscation

Private

Series C

Lexington, Massachusetts, United States

11-50

www.accenttx.com/

Biotechnology

Medical

Pharmaceutical

Therapeutics

Funding Rounds

Series C

OBF

obfuscation

Series B

OBF

obfuscation

Series A

OBF

obfuscation

Key People

Robert A. Copeland: President & Co-Founder
Past Role: Accent Therapeutics, Chief Scientific Officer
Nicole Heifner: CFO
Past Role: Intellia Therapeutics, CAO

Details

Legal Name

Accent Therapeutics, Inc.

Operating Status

Active

Company Type

For Profit

Founders

Robert A. Copeland

About the Company

Accent Therapeutics is a biopharmaceutical company developing oncology-focused, small molecule therapies in the emerging field of epitranscriptomics. This field of biology encompasses post-transcriptional chemical modifications of RNA that provide cells with a unique mechanism for regulating proteins critical for cellular growth and

differentiation. By targeting cancer-linked RNA-modifying proteins (RMPs) with precision therapies, they aim to translate extraordinary science into life-changing therapies for patients.

Phone Number

(339) 970-7400

Contact Email

contactus@accenttx.com.

Predictions & Insights

Growth Insight

See this Growth Insight

Accent Therapeutics is

Lorem

to be growing

Top Contributing Factors

Operations Contraction

Growth Prediction

See this Growth Prediction

Top Contributing Factors

Key Employee Changes

Products & Services

ATX-559

ATX-559 is a first-in-class oral inhibitor targeting DHX9, a helicase involved in replication stress in various cancers, designed to inhibit tumor growth in patients with advanced solid tumors.

ATX-295

ATX-295 is an oral inhibitor of KIF18A, a mitotic kinesin motor protein, aimed at treating cancers with chromosomal instability such as ovarian and triple-negative breast cancer.

Research & Development

Accent Therapeutics is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated

...

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series C - Accent Therapeutics	13	obfuscated obfuscation	Mirae Asset Capital Life Science	Series C
obfuscated obfuscation	Series C - Accent Therapeutics	13	obfuscated obfuscation	Mirae Asset Capital Life Science	Series C
obfuscated obfuscation	Series C - Accent Therapeutics	13	obfuscated obfuscation	Mirae Asset Capital Life Science	Series C
obfuscated obfuscation	Series C - Accent Therapeutics	13	obfuscated obfuscation	Mirae Asset Capital Life Science	Series C
obfuscated obfuscation	Series C - Accent Therapeutics	13	obfuscated obfuscation	Mirae Asset Capital Life Science	Series C

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series C - Accent Therapeutics	13	obfuscated obfuscation	Mirae Asset Capital Life Science	Series C
obfuscated obfuscation	Series C - Accent Therapeutics	13	obfuscated obfuscation	Mirae Asset Capital Life Science	Series C
obfuscated obfuscation	Series C - Accent Therapeutics	13	obfuscated obfuscation	Mirae Asset Capital Life Science	Series C
obfuscated obfuscation	Series C - Accent Therapeutics	13	obfuscated obfuscation	Mirae Asset Capital Life Science	Series C
obfuscated obfuscation	Series C - Accent Therapeutics	13	obfuscated obfuscation	Mirae Asset Capital Life Science	Series C

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
Bristol-Myers Squibb	—	Series C - Accent Therapeutics	—
Bristol-Myers Squibb	—	Series C - Accent Therapeutics	—
Bristol-Myers Squibb	—	Series C - Accent Therapeutics	—
Bristol-Myers Squibb	—	Series C - Accent Therapeutics	—
Bristol-Myers Squibb	—	Series C - Accent Therapeutics	—